Baird served as co-manager on this offering
AboutNewLink Genetics Corporation (“NewLink” or the “Company”) (NASDAQ: NLNK) recently completed a follow-on offering of 4,600,000 shares of common stock at a price of $11.40 per share, generating gross proceeds of approximately $52.4 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including regulatory, clinical trial, research and development, general and administrative, and manufacturing expenses.
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink’s lead product candidate, HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment with the FDA. NewLink has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer. The Company’s additional HyperAcute product candidates in clinical development include its HyperAcute Lung and its HyperAcute Melanoma product candidates. To date, the Company’s HyperAcute product candidates have been dosed in more than 300 cancer patients, either as a monotherapy or in combination with other therapies, and have demonstrated a favorable safety profile. NewLink is based in Ames, Iowa.
For additional information about this transaction, please contact:
- January 2013
- NewLink Genetics Corporation
- Target Geography
- North America